Stock Trading Canary← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Ignelzi Troy A.
Chief Financial Officer | Officer
Identity: SEC owner CIK matched through an unambiguous cached owner-name crosswalk · Reporting-owner CIK: 0001579829
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 1
- Purchases · 24M
- 2
- Average purchase
- $122.3K
- Median purchase
- $122.3K
- Gross purchase value
- $244.5K
Companies: Rapport Therapeutics, Inc.
2 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-10-21 | Rapport Therapeutics, Inc. | RAPP | Chief Financial Officer | Officer | $143.6K | Open filing |
| 2025-03-13 | Rapport Therapeutics, Inc. | RAPP | Chief Financial Officer | Officer | $101.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -5.8% | -5.8% | -10.1% |
| 20D | 1Small Sample | 100.0% (1/1) | 0.0% (0/1) | -9.3% | -9.3% | -9.3% |
| 60D | 1Small Sample | 100.0% (1/1) | 100.0% (1/1) | +17.8% | +17.8% | +17.8% |
| 120D | 1Small Sample | 100.0% (1/1) | 100.0% (1/1) | +34.8% | +34.8% | +34.8% |
Research patterns
- First purchase in 12M
- 1/1
- Large purchase ≥ $100k
- 2/2
- Cluster buying · 15D
- 1/2
- Buying the dip
- 1/1
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.